Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Presentations

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • 2025 AGM
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • Company Info

  • Overview
  • Presentations
  • Contacts
  • FAQ

Aurinia 2025 Corporate Presentation

EULAR 2022: Voclosporin for Lupus Nephritis: Results of the Two-Year AURORA 2 Continuation Study

Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

European Renal Association Congress 2022: Early Reductions in Proteinuria with Voclosporin Treatment across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

European Renal Association Congress 2022: Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study

Clinical Program Update

American College of Rheumatology Convergence 2021

American Society of Nephrology Kidney Week 2021

EULAR 2021: Real-world Economic Implications of Achieving Low Disease Activity in Lupus Nephritis - Presented by Dr Paola Mina-Osorio

EULAR 2021: Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study - Presented by Dr Amit Saxena

rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.